The patient later relapsed, developing progression at a new extramedullary site; however, notably, the expression of NY-ESO-1 and LAGE-1 remained absent until the patient’s death at 2 years post-infusion, suggesting the role of ongoing immune surveillance and antigen escape in MM. The gene discussed is CTAG2; the disease is Miyoshi myopathy.